The approval covers 20 mg/200 mL (0.1 mg/mL) and 40 mg/200 mL (0.2 mg/mL) single-dose infusion bags, which are therapeutic equivalents to the Reference Listed Drug from Hikma International Pharmaceuticals LLC. Shares of Caplin Point Laboratories Ltd ended at ₹2,024.90, down by ₹5.00, or 0.25%, on the BSE.
